UNION KOREA PHARM CO.,Ltd

As of June 30, 2026, UNION KOREA PHARM CO.,Ltd has 26.55M shares outstanding.

As of June 30, 2026, UNION KOREA PHARM CO.,Ltd maintains a current ratio of 1.26, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.47, indicating elevated leverage, while an interest coverage ratio of -9.16 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, UNION KOREA PHARM CO.,Ltd posted a negative return on equity (ROE) of -137.86, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.67, reflecting losses generated across the asset base. The company generates approximately 185.12M in revenue per employee across its workforce of 137.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.80 indicates how many times UNION KOREA PHARM CO.,Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, UNION KOREA PHARM CO.,Ltd recorded 3.01B in income tax expense. The company reported a pretax loss of -21.29B and -24.30B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on August 27, 2026, UNION KOREA PHARM CO.,Ltd's stock has gained approximately 200.00% over the past 52 weeks. The 50-day moving average sits at 4,541.70, while the 200-day moving average is 5,159.00.

Over the twelve months ended June 30, 2026, UNION KOREA PHARM CO.,Ltd generated 25.45B in revenue and converted that into -24.30B in net income, yielding earnings per share of -4,761.79. EBITDA reached -13.89B, while operating income came in at -15.38B.

As of June 30, 2026, UNION KOREA PHARM CO.,Ltd holds 37.43B in cash and equivalents against 5.21B in total debt, resulting in a net debt position of -32.03B. Total book value stands at 33.68B, with working capital of 11.09B providing operational flexibility.

UNION KOREA PHARM CO.,Ltd produced -1.56B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -78.57M in capital expenditures, free cash flow totaled -1.64B - equivalent to -321.90 per share.

Over the twelve months ended June 30, 2026, UNION KOREA PHARM CO.,Ltd posted a gross margin of 10.00, reflecting its pricing power and cost economics. The operating margin of -60.41 and net profit margin of -95.48 provide insight into operational efficiency.

UNION KOREA PHARM CO.,Ltd's most recent stock split took place on August 28, 2026 with a 3:1 split ratio.